Navigation Links
Oncolytics Biotech Inc. Investigators Present Interim U.S. REOLYSIN(R) Phase II Sarcoma Trial Data
Date:11/6/2008

------------------------------

Chordoma 5* SD

-------------------------------------------------------------------------

Unspecified Spindle Cell 5* SD

-------------------------------------------------------------------------

* patients still on study

An oral presentation covering results of the trial (REO 014) is also scheduled to be delivered at the Connective Tissue Oncology Society (CTOS) annual meeting, being held in London, U.K. from November 13-15, 2008.

The slides will be available on the Oncolytics' website after the presentation.

Dr. Anders Kolb of the Nemours Center for Childhood Cancer Research is also scheduled to present a poster at the CTOS meeting entitled "Systemic Administration of REOLYSIN Inhibits Growth of Human Sarcoma Xenografts Alone and in Combination with Cisplatin and Radiation."

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit http://www.oncolyticsbiotech.com.

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the implication of the materials presented at this meeting with respect to REOLYSIN(R), the Company's expectations related to the results of trials investigating delivery of REOLYSIN(R), the Company's analysis of the results of the Phase II trial, and the Company's belief as to the potential of REOLYSIN(R) as a cancer therapeutic, involve known
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech Inc. Announces U.S. Phase II Sarcoma Clinical Trial Conference Call
2. Oncolytics Biotech Inc. Announces 2008 Third Quarter Results
3. Oncolytics Biotech Inc. Announces Decision to Pursue Phase II/III Pivotal Clinical Trial
4. Oncolytics Biotech Inc. Announces Clinical Update Conference Call
5. Oncolytics Biotech Inc. Collaborators Present Positive Phase I/II Combination REOLYSIN(R) and Paclitaxel/Carboplatin Results at iSBTc Annual Meeting
6. Oncolytics Biotech Inc. Collaborators Present Positive Combination REOLYSIN(R) and Docetaxel Results at iSBTc Annual Meeting
7. Oncolytics Biotech Inc. Collaborators to Present Combination REOLYSIN(R) and Paclitaxel/Carboplatin Results at iSBTc Annual Meeting
8. Oncolytics Biotech Inc. Collaborators to Present Combination REOLYSIN(R) and Docetaxel Results at iSBTc Annual Meeting
9. Oncolytics Biotech Inc. Collaborators Present Reovirus and Melanoma Research at EORTC-NCI-AACR Symposium
10. Oncolytics Biotech Inc. Collaborators to Present Preclinical Combination REOLYSIN(R) and Cisplatin Research at EORTC-NCI-AACR Annual Meeting
11. Media Advisory - Oncolytics Biotech Inc. to Present at BIO Investor Forum 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... ... ... The latest addition to the Mettler-Toledo PCE portfolio is the ... the pharmaceutical and healthcare industry can use the LSS to print track-and-trace labels for ... Station can be fully integrated into the production line and is also available as ...
(Date:9/3/2015)... RICHMOND, BC , Sept. 3, 2015 /PRNewswire/ - ... is pleased to announce its study " Sensitivity of ... antibody detection is enhanced by its affinity for HIV ... Journal of Clinical Virology.  This study highlights INSTI,s ability ... researchers presented their findings at the 8 th ...
(Date:9/3/2015)... ... September 03, 2015 , ... Michigan-based technology startup ... early 2016. , The device, called the Halo H1, is a wearable ... sensing technology. These sensors track trending interstitial fluid levels in the body, in ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... regulatory compliance, quality systems, analytical testing, education and consulting services for the ... in medical device products/processes development, design control, validation, quality assurance and regulatory ...
Breaking Biology Technology:Print and Verify Labels On The Production Line With New Label Serialization Stations 2Print and Verify Labels On The Production Line With New Label Serialization Stations 3bioLytical's INSTI HIV Test Detects gp41 specific IgM Antibodies 2bioLytical's INSTI HIV Test Detects gp41 specific IgM Antibodies 3Technology Startup Halo Wearables to Unveil Non-Invasive Hydration Monitoring Device Early 2016 2NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 2NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 3NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 4NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 5NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 6NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 7
... ... distribute feedstock for E-Fuel MicroFueler™ , ... Sacramento (Vocus) June 4, 2009 -- California Governor Arnold Schwarzenegger joined ... Corp. unveiled the final production model of the revolutionary E-Fuel MicroFueler, a portable micro-refinery ...
... WEBCAST WEDNESDAY, JUNE 10, 2009 , , SAN ... NBIX ) announced today that Kevin Gorman, President and Chief ... 8th Annual Needham Life Sciences Conference in New York. ... 10, 2009 at 1:30 p.m. Eastern Time (ET)/10:30 a.m. Pacific ...
... , BRAINTREE, Mass., June 4 Haemonetics Corporation (NYSE: ... for the District of Massachusetts has made a ruling in ... January 2009, a jury issued a verdict in favor of ... a U.S. Haemonetics patent. The jury awarded Haemonetics $15.7 ...
Cached Biology Technology:GreenHouse Energy, Governor Schwarzenegger Join in Driving the Future of Fueling in California 2GreenHouse Energy, Governor Schwarzenegger Join in Driving the Future of Fueling in California 3Neurocrine Biosciences to Present at the 8th Annual Needham Life Sciences Conference 2Haemonetics Receives Favorable Ruling in Patent Lawsuit against Competitive Technology 2
(Date:8/20/2015)... , Aug. 20, 2015 The wearable ... that are active and healthy. However, wearable technology ... hospital environment to help improve diagnostic capabilities and ... from the Wearable Technologies Conference 2015 , ... applications for wearables in healthcare.    ...
(Date:8/18/2015)... 2015  Navitas today announced that it ... Submission Content Management webinar scheduled on August ... to the Implementation of Regulatory Submission Standards ... industry, vendors, health authorities, consultants and the ... a standard method of implementing electronic submission ...
(Date:8/12/2015)... 12, 2015 As the digital ... innovation and advanced biometrics technology is accelerating beyond expectations.  ... rely on using their credit cards, the digital currency, ... for payment services led by companies in the space ... Google, Inc. (NASDAQ: GOOG ), Apple Inc. (NASDAQ: ...
Breaking Biology News(10 mins):Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 2Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 4Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 6
... at Iowa State University have discovered a previously unknown ... Yanhai Yin, an assistant professor in genetics, development and ... called brassinosteroids. The hormone controls the growth of cells. ... how large the plant grows, says Yin. , "Previously, ...
... the oldest synthetic malaria drug, the methylene blue stain, ... a significant contribution to the long-term eradication called for ... study on 160 children with malaria in Burkina Faso, ... have shown that in combination with newer malaria drugs, ...
... Some researchers hope to turn plants into a renewable, ... have to learn how to convert plant biomass into ... efficiently. In new research, chemists have successfully converted cellulose ... the building block called HMF in one step. ...
Cached Biology News:ISU researcher identifies genetic pathway responsible for much of plant growth 2Old stain in a new combination 2Old stain in a new combination 3Plastic that grows on trees, part two 2
... to SARA ( Abpromise for all ... Synthetic peptide: PVPKEMEQPV QTEEEDVELP conjugated to KLH, ... fly (Drosophila melanogaster) SARA. Conserved sequence ... Gene ID: 9372 ...
Rabbit polyclonal to Bag5 ( Abpromise for all tested applications). entrezGeneID: 9529 SwissProtID: Q9UL15...
AADAC Immunogen: AADAC (NP_001077, 201 a.a. ~ 301 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
RNA polymerase sigma 70 Immunogen: Recombinant, full length protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: